BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 16 July 1997
"While the US Centers for Disease Control and Prevention covers reported cases of AIDS and a broad estimate of HIV+ cases, the agency does not provide estimates on the number of HIV+ patients receiving drug therapy," said Joy Scott, CEO, Scott-Levin. "Scott-Levin's audit provides this unique data to those interested in the current state of HIV+ therapy."
The audit projects data from general and family practitioners, internists, and infectious disease specialists who are actively treating HIV+ patients.
-0-
*T
The first edition of the audit, now available from Scott-Levin, shows:
-- A projected 316,890 HIV+ patients are seeking treatment during the first quarter of 1997.
-- 14% of visits for HIV+ status do not include drug therapy
-- Merck's Crixivan is projected as the most-prescribed protease inhibitor,used in the first quarter of 1997 (80,200 patients).
-- Patient demographics indicate that of patients seeking treatment, 75% are male and 25% are female.
-- Patient mix by race is 49% white, 33% black, and 16% Hispanic
-- About 40% of patients' medical and drug therapy is covered by Medicaid, the most common form of payment.
-- Most patient contacts (63%) take place in a doctor's office, with 18% of visits at a hospital clinic location and 11% of contacts in the hospital itself.
"We hope and strongly feel that the data provided in the HIV Therapy Audit will help the pharmaceutical industry to better understand and meet the needs of HIV+ patients," said Scott.
For more information, contact John Ross or Christie Robertson at 800/982-5613.
Scott-Levin, a division of PMSI/Scott-Levin Inc., provides consulting and communications services to pharmaceutical companies worldwide.
*T
--30--sy/sf* gt/sf
CONTACT: Scott-Levin John Ross or Christie Robertson, 215/860-0440 marketing@scottlevin.com
REPEATS: New York 212-752-9600 or 800-221-2462; Boston 617-236-4266 or 800-225-2030; SF 415-986-4422 or 800-227-0845; LA 310-820-9473 Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
970716
BW970708
Copyright © 1997 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .